Navigation Links
A Successful Launch of a New Oncology Product Requires Global Teams & Planning
Date:11/1/2012

CHAPEL HILL, N.C., Nov. 1, 2012 /PRNewswire/ -- Global Strategic Marketing (GSM) organizations in oncology and other critical therapeutic areas often face crowded markets that require high performance and proficiency to be successful.

Add to this increasing regulatory challenges, regional differences and the competitive nature of the oncology marketplace and it is easy to understand why GSM organizations to constantly assess their budgets and resource planning strategies to ensure a successful product launch.

To help marketing leaders throughout the pharma and medical device industries better equip their global strategy groups, Best Practices, LLC conducted and delivered "Oncology Global Strategic Marketing: Benchmarking Budget Levels & Service Scope," a primary research study which identifies essential insights for Oncology-GSM leaders in budgeting and strategic planning. 

This report seeks to help companies understand the investment levels, marketing activities, timing and structures needed to successfully steer products and pipeline programs through the complex Oncology marketplace.

Executives can use this 75-page report to compare their global strategic marketing budget, staffing and services levels with industry averages to enhance their current practices.

Sample study benchmarks available in this report include:

  • GSM staffing benchmarks by role, by development phase, by number of oncology programs and per $100M in oncology sales
  • Outsourced and in-house labor dedicated to traditional and emerging markets
  • GSM organizational structure
  • Role of the GSM function for activities such as market intelligence, marketing, advocacy and KOL management
  • Spending benchmarks around key GSM activities within marketing, market intelligence and advocacy
  • Oncology GSM spending by phase of clinical development

Research participants included Global Strategic Marketing leaders supporting oncology organizations at 17 companies, including 11 of the Top 25 pharma companies. The study included both large, established and small, emerging oncology companies to provide broadest insights.

A complimentary excerpt of the research report is available at: http://www3.best-in-class.com/rr1185.htm.

For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.

BEST PRACTICES, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies.

The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
8. Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
9. Acuo Technologies Grows European Business and Achieves Successful Connectathon Results in Bern, Switzerland
10. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
11. Concord Medical Announces its Successful Closing of the Acquisition of 52% Ownership in Changan Hospital and Provides Guidance for Financial Results of the Second Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 23, 2017  The particle counters market ... 2021 from USD 275.9 million in 2016, at ... full report: http://www.reportlinker.com/p04718602-summary/view-report.html The ... pharmaceutical R&D, and growth in manufacturing industries in ... growth for particle counters. On the other hand, ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device company that ... pain, today reported financial results for the three months and ... Accomplishment & Highlights: Achieved revenue of $228.5 ... as reported, over the prior year U.S. revenue ... the prior year International revenue of $55.2 ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Miami Beach to host its Swirl: Miami Wine Tasting Event on March 28, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... exciting, new, interactive publication where generations converge and explore the world from different ... worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find greater ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... and community for those in the fight against cancer, has produced a seminal ... success. HRA will release top-line findings in a webinar, Defining Compassionate Care ...
Breaking Medicine News(10 mins):